Metastatic renal cell carcinoma has a poor prognosis, requiring system
ic therapy, in addition to radical nephrectomy. Since August 1989, 50
patients were treated with continuous, systemic, chronobiological infu
sion of FUDR (floxuridine) at our Institution. We reported 11.7 % of o
bjective responses, a long period of stable disease and low toxicity.
We also compared our actuarial survival with the results obtained with
recombinant IL-2 treatment.